ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ALK
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ALK
11
trial(s) found.
NCT06834074
Advanced
Available
Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (
NVL-655-EAP
)
ALK inhibitor,fourth generation
ALK-positive non-small-cell lung cancer
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (AVAILABLE)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (AVAILABLE)
NCT06765109
Advanced
Phase 3
Recruiting
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (
ALKAZAR
)
ALK/RET inhibitor
ALK inhibitor,fourth generation
ALK inhibitor,second generation
Lymphoma
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06707610
Advanced
Phase 1
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors (
ALK202-01
)
anti-EGFR/cMET antibody-drug conjugate
+ ALK-202
Cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
NCT06656390
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors (
ALK201-01
)
anti-FGFR2b antibody-drug conjugate
+ ALK-201
Cancer
Solid tumour
NSW
2500 - Wollongong - Cancer Care Wollongong
NCT06333899
Paed
Phase 1
Recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
CONNECT-TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05384626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1) (
NVL-655-01
)
ALK inhibitor,fourth generation
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04774718
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (
GO42286
)
ALK/RET inhibitor
ALK inhibitor,second generation
Central nervous system cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
+ ALK inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03093116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (
TRIDENT-1
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Epworth Freemasons (COMPLETED)
SA
5042 - Bedford Park - Flinders Medical Centre (COMPLETED)
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ ALK inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (9)
Status unknown (1)
Recruitment Country and State
NSW (11)
VIC (5)
QLD (4)
WA (2)
NZ (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (6)
Phase 3 (1)
Trial Type
Advanced (8)
Paed (3)
Cancer Therapy Class
ALK
82%
ROS1
55%
RET
18%
TRK
18%
MET
18%
FGFR2
9%
FGFR2b
9%
DPD
9%
orotate phosphoribosyltransferase
9%
MEK
9%
PKC
9%
ATR
9%
BCR-ABL1
9%
CDK4
9%
CDK6
9%
CRAF
9%
EGFR
9%
FLT3
9%
JAK1
9%
JAK2
9%
KIT
9%
PDGFR
9%
PDGFRA
9%
PI3K
9%
RAF
9%
SMO
9%
SRC
9%
VEGFR
9%
YES1
9%
mTOR
9%
mTORC1
9%
mTORC2
9%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
2031 - Randwick - Sydney Children's Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3002 - East Melbourne - Epworth Freemasons (1)
5042 - Bedford Park - Flinders Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Central nervous system cancer
Neurological cancer
Haematological malignancy
Lymphoma
ALK fusion-solid tumour
ALK-positive non-small-cell lung cancer
Solid tumour with ongenic fusion
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Colorectal cancer
Cutaneous melanoma
Gastrointestinal cancer
Lower gastrointestinal cancer
Melanoma
Skin cancer
Uveal melanoma
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy